Eli Lilly Gets CHMP Positive Opinion for Covid-19 Treatments
06 March 2021 - 4:24AM
Dow Jones News
By Colin Kellaher
Eli Lilly & Co. on Friday said the European Medicines
Agency's Committee for Medicinal Products for Human Use issued a
positive scientific opinion for the company's antibody-based
Covid-19 drugs aimed at helping people at high risk of severe
disease avoid hospitalization.
The Indianapolis drugmaker said the opinion covers its
monoclonal antibody bamlanivimab alone and in combination with one
named etesevimab for the treatment of confirmed Covid-19 in
patients ages 12 years and older who don't need supplemental oxygen
and are at high risk of progressing to severe Covid-19.
Monoclonal antibodies are engineered proteins that mimic the
immune system's ability to fight off viruses.
Eli Lilly said European Union member states can consider the
opinion when making decisions on use of the therapies at a national
level before a formal marketing authorization is issued by the
European Commission.
The company noted that other countries look to CHMP advice to
support their own reviews.
"We hope this opinion will accelerate those reviews and
authorizations, particularly in low- and middle-income countries,
where Lilly is prepared to provide doses at greatly reduced costs
or free of charge," the company said.
The Food and Drug Administration has granted emergency-use
authorization to bamlanivimab and the bamlanivimab/etesevimab
combination.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 05, 2021 12:09 ET (17:09 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Apr 2024 to May 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From May 2023 to May 2024